<DOC>
	<DOCNO>NCT01666249</DOCNO>
	<brief_summary>The anti-Rh immunoglobulin immunobiological contain high concentration specific antibody factor D `` neutralizes '' D antigen present Rh-positive fetal red blood cell ( Rh + ) , pass bloodstream Rh-negative pregnant woman ( Rh ) . This immunization study clinical assessment anti-Rh immunoglobulin ( KamRho-DÂ® ) Rh Coombs negative woman risk sensitization .</brief_summary>
	<brief_title>Clinical Efficacy Postpartum Immunization Rh Coombs Negative Women With Sensitization Risk .</brief_title>
	<detailed_description>This immunization , non-randomized phase III study woman participant RH Coombs negative receive one dose 1500 IU anti-Rh immunoglobulin intramuscularly follow six month verification negative Coombs maintenance . Safety evaluation data include report adverse event ( include type , frequency , intensity , seriousness , severity action take related investigational product ) .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Fetomaternal Transfusion</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Agree participate , sign date Informed Consent ; 18 year old old ; Mothers Rhnegative , negative indirect Coombs analyze gel agglutination method , whose delivery Rh positive baby . Be participate simultaneously participate another clinical trial within last 12 month ; Mothers allergic component formula ; Mothers history IgA deficiency IgA antibody present ; Mothers history autoimmune hemolytic anemia hemolysis preexist risk hemolysis ; Mothers indirect Coombs test positive beginning treatment ; Rhnegative mother whose delivered Rhnegative baby ; Abnormalities coagulation system ; Patients make use vaccine make live pathogen last 03 month make study ; Patients clinical diagnosis prenatal liver / severe nephropathy ; Principal Investigator study criterion ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>FMH ; anti-Rh ; efficacy</keyword>
</DOC>